Upstream’s proprietary drug discovery platform utilizes chemoinformatics which combines chemistry and computer-aided design to accelerate the speed and reduce the cost of discovering drugs to treat disease. Testing at McGill’s Institute of Parasitology will be directed by Armando Jardim.
Upstream anticipates that the company’s first generation drug candidates will undergo in vivo (in animals) efficacy testing before the end of the third quarter of 2008.
Joel Bellenson, CEO of Upstream, said: “The testing will evaluate the company’s second generation drug candidates for anti-parasite activity and safety to human cells.”